Astrazeneca Plc (AZN.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2021 | 03-2021 | 12-2020 | 09-2020 | 06-2020 | |
| Sales | 8,220,000 | 7,320,000 | 7,410,000 | 6,578,000 | 6,275,000 |
| Cost of Goods | 2,191,000 | 1,864,000 | 1,525,000 | 1,370,000 | 984,000 |
| Gross Profit | 6,029,000 | 5,456,000 | 5,885,000 | 5,208,000 | 5,291,000 |
| Operating Expenses | 4,902,000 | 3,561,000 | 6,227,000 | 3,886,000 | 4,007,000 |
| Operating Income | 1,127,000 | 1,895,000 | -342,000 | 1,322,000 | 1,284,000 |
| Interest Expense | 326,000 | 303,000 | 287,000 | 324,000 | 329,000 |
| Other Income | -37,000 | 16,000 | 1,796,000 | -145,000 | 6,000 |
| Pre-tax Income | 764,000 | 1,608,000 | 1,167,000 | 853,000 | 961,000 |
| Income Tax | 214,000 | 46,000 | 162,000 | 202,000 | 223,000 |
| Net Income Continuous | 550,000 | 1,562,000 | 1,005,000 | 651,000 | 738,000 |
| Minority Interests | 0 | -1,000 | 7,000 | -3,000 | 18,000 |
| Net Income | $550,000 | $1,561,000 | $1,012,000 | $648,000 | $756,000 |
| EPS Basic Total Ops | 0.42 | 1.19 | 0.78 | 0.49 | 0.58 |
| EPS Basic Continuous Ops | 0.42 | 1.19 | 0.78 | 0.49 | 0.58 |
| EPS Diluted Total Ops | 0.42 | 1.18 | 0.78 | 0.49 | 0.58 |
| EPS Diluted Continuous Ops | 0.42 | 1.18 | 0.78 | 0.49 | 0.58 |
| EBITDA(a) | $1,843,000 | $2,708,000 | $2,251,000 | $1,978,000 | $2,000,000 |